CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 424 enrolled
Drug / intervention
Duloxetine (DLX) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00945945
NCT00945945Phase 3Completed
CompareCT.gov

A Phase 3b Study to Assess the Efficacy of Duloxetine 60 mg Once Daily Compared With Placebo on the Reduction of Pain Caused by Osteoarthritis of the Knee, in a 13-week, Double-blind, Randomized Study

Eli Lilly and Company·interventional·Posted Jul 24, 2009·Updated Mar 8, 2011

In Brief

A Phase 3 clinical trial evaluating Duloxetine (DLX) and Placebo (PLA) for Osteoarthritis Knee Pain. Completed, enrolled 424 participants across 26 sites in 8 countries.

Detailed Summary

The primary purpose of this study is to determine if duloxetine 60 mg once daily (QD) reduces pain severity in patients with osteoarthritis (OA) knee pain compared with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis Knee Pain
CountriesGermany, Greece, Puerto Rico, Romania, Russia, Spain, Sweden, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 24, 2009
Enrollment StartJul 1, 2009
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.9 years ago

Interventions

Duloxetine (DLX)drug

dose daily by mouth

Placebo (PLA)drug

Placebo Comparator daily by mouth